AAN 2026 | Lifestyle interventions versus anti-amyloid therapies in early AD: comparative review of RCTs

Majid Fotuhi, MD, PhD, Johns Hopkins University, Washington, D.C., discusses findings from a comparative review of randomized controlled trials (RCTs) evaluating multidomain lifestyle interventions and anti-amyloid monoclonal antibodies in mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Dr Fotuhi highlights how exercise, Mediterranean diet, and cognitive training were associated with improvements in cognitive scores, while monoclonal antibodies had more subtle impacts on cognitive function. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.